Product Description
NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. (Sourced from: https://clinicaltrials.gov/study/NCT06332807)
Mechanisms of Action: Gene Therapy,PAH
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NGGT (Suzhou) Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for NGGT-002](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Phenylketonurias
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NGGT002-P-2301 | P2 |
Not yet recruiting |
Phenylketonurias |
2030-12-30 |